Brind.

Immuneering (United States) appointed Leerink partners as a financial advisor for a private placement, effective August 27, 2025.

1 report, 1 independent Updated Aug 27

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Immuneering (United States)Leerink partners

Keep exploring

The entities involved

Immuneering (United States)
company in Cambridge, United States

Nothing else this week.
Leerink partners
U.S. investment bank
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38

Coverage

Newest first; wire copies grouped

Aug 27GlobeNewswireImmuneering Announces Closing of $25 Million Private Placement CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on